Summary
Fifteen patients with advanced renal cell carcinoma were treated with Menogaril, 200 mg/m2 by one-hour, intravenous infusion at four-week intervals. No objective regressions were observed. Median time to progression was two months, and median survival was seven months. All patients experienced neutropenia. Platelet toxicity was negligible. Venous irritation and phlebitis at the infusion site was seen in 47% of patients. Menogaril as administered in this protocol is ineffective in advanced renal cell carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hahn RG, Bauer M, Wolter J, Creech R, Bennett JM, Wampler G: Phase II study of single-agent therapy with megesterol acetate, VP16–213, Cyclophosphamide, and dianhydro galactitol in advanced renal cell cancer. Cancer Treat Rep 63:513–515, 1979
Poster DS, Bruno S, Penta JS, Pinna K, Vilk P, Macdonald JS: Current status of chemotherapy, hormonal therapy, and immunotherapy in the treatment of renal cell carcinoma. Am J Clin Oncol (CCT) 5:53–60, 1982
Scher HI, Yagoda A, Ahmed T, Budman D, Sordillo P, Watson RC: Phase II trial of 4-demethoxy dounorubicin (DMDR) for advanced hypernephroma. Cancer Chemother Pharmacol 14:79–80, 1985
Neil GL, Fuentzel SL, McGovren JP: Therapy of mouse tumors with 7-con-O-methylnogarol and other analogs of the anthracycline antibiotic, nogalamycin. Cancer Treat Rep 63:1971–1978, 1979
McGovren JP, Neil GL, Denlinger RH, Hall TL, Crampton SL, Sivenberg JA: Chronic cardiotoxicity studies in rabbits with 7-con-O-methylnogarol, a new anthracycline antitumor agent. Cancer Res 39:4849–4855, 1979
Bhuyan BK, McGovren JP, Crampton SL: Intracellular uptake of 7-con-O-methylnogarol and Adriamycin by cells in culture and its relationship to cell survival. Cancer Res 41:882–887, 1981
Li LH, Kuentzel SLK, Murch LL, Pschigoda LM, Krueger WC: Comparative biological and biochemical effects of nogalamycin and its analogues on L-1210 leukemia. Cancer Res 39:4816–4822, 1979
Adams EG, Crampton SL, Bhyuyan BK: Effect of 7-con-0-methylnogarol on DNA synthesis, survival, and cell cycle progression of Chinese hamster ovary cells. Cancer Res 41:4981–4987, 1981
Egorin MJ, vanEcho DA, Whitacre MY, Forrest A, Sigman LM, Engisch KL, Aisner J: Human Pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic, Menogaril (7-OMEN, NSC-269148) and their correlation with clinical toxicities. Cancer Res 46:1513–1520, 1986
Long HJ, Powis G, Schutt AJ, Moertel CG: Phase I and pharmacokinetic study of menogaril administration as a 72-hour continuous i.v. infusion. Cancer Treattion as a 72-hour continuous i.v. infusion. Cancer Treat Rep 71:593–598, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Long, H.J., Hauge, M.D., Therneau, T.M. et al. Phase II evaluation of menogaril in patients with advanced hypernephroma. Invest New Drugs 9, 261–262 (1991). https://doi.org/10.1007/BF00176980
Issue Date:
DOI: https://doi.org/10.1007/BF00176980